Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 12, Issue 2, 2010, Pages 167-177

  Vilsboll T ^a   Rosenstock, J ^b   Yki Jarvinen H ^c   Cefalu, W T ^d   Chen, Y ^e   Luo, E ^e   Musser, B ^e   Andryuk, P J ^e   Ling, Y ^e   Kaufman, K D ^e   Amatruda, J M ^e   Engel, S S ^e   Katz, L ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b DALLAS DIABETES AND ENDOCRINE CENTER AT MEDICAL CITY   (United States)

^c UNIVERSITY OF HELSINKI   (Finland)

^d LOUISIANA STATE UNIVERSITY   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Dipeptidyl peptidase 4 inhibitor; DPP 4 inhibitor; Insulin; Sitagliptin; Type 2 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PLACEBO; SITAGLIPTIN;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY MASS; CHRONIC PYELONEPHRITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DIET RESTRICTION; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROENTERITIS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMORRHOID; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; LEUKOCYTOCLASTIC VASCULITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

EID: 73349119110     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2009.01173.x     Document Type: Article

References (33)

1. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999, 281:2005-2012.
2. Hermansen K, Davies M, Derezinski T, Martinez RG, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006, 29:1269-1274.
3. Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006, 49:442-451.
4. Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Jarvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005, 28:254-259.
5. Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care 2005, 28:1282-1288.
6. Kennedy L, Herman WH, Strange P, Harris A. Impact of active versus usual algorithmic titration of basal insulin and point-of-care versus laboratory measurement of HbA1c on glycemic control in patients with type 2 diabetes: the Glycemic Optimization with Algorithms and Labs at Point of Care (GOAL A1C) trial. Diabetes Care 2006, 29:1-8.
7. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003, 26:3080-3086.
8. Holman RR, Thorne KI, Farmer AJ. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007, 357:1716-1730.
9. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005, 143:559-569.
10. Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C, Linn T. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet 2008, 371:1073-1084.
11. Raskin P, Allen E, Hollander P. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005, 28:260-265.
12. Nauck MA, Duran S, Kim D. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007, 50:259-267.
13. Guler S, Vaz JA, Ligthelm R. Intensification lessons with modern premixes: from clinical trial to clinical practice. Diabetes Res Clin Pract 2008, 81((Suppl. 1)):S23-S30.
14. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002, 26((Suppl. 3)):S18-S24.
15. Karasik A, Aschner P, Katzeff H, Davies MJ, Stein PP. Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials. Curr Med Res Opin 2008, 24:489-496.
16. Herman GA, Bergman A, Stevens C. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006, 91:4612-4619.
17. Xu L, Dalla Man C, Charbonnel B. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach. Diabetes Obes Metab 2008, 10:1212-1220.
18. Brazg R, Xu L, Dalla Man C, Cobelli C, Thomas K, Stein PP. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. Diabetes Obes Metab 2007, 9:186-193.
19. Williams-Herman D, Round E, Swern AS. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocr Disord 2008, 8:14.
20. Breda E, Cobelli C. Insulin secretion rate during glucose stimuli: alternative analyses of C-peptide data. Ann Biomed Eng 2001, 29:692-700.
21. Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006, 28:1556-1568.
22. Stettler C, Stahl M, Allemann S. Association of 1,5-anhydroglucitol and 2-h postprandial blood glucose in type 2 diabetic patients. Diabetes Care 2008, 31:1534-1535.
23. Dungan KM, Buse JB, Largay J. 1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care 2006, 29:1214-1219.
24. Yki-Jarvinen H. Toxicity of hyperglycaemia in type 2 diabetes. Diabetes Metab Rev 1998, 14((Suppl. 1)):S45-S50.
25. Rachman J, Payne MJ, Levy JC, Barrow BA, Holman RR, Turner RC. Changes in amylin and amylin-like peptide concentrations and beta-cell function in response to sulfonylurea or insulin therapy in NIDDM. Diabetes Care 1998, 21:810-816.
26. Ryan EA, Imes S, Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care 2004, 27:1028-1032.
27. Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007, 9:733-745.
28. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.
29. Rosenstock J, Rendell M, Gross J, Fleck P, Wilson C, Mekki Q. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1c without increasing weight gain or hypoglycemia. Diabetes 2008, 57((Suppl. 1)):A132-A133.
30. Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007, 50:1148-1155.
31. Ahren B, Schweizer A, Dejager S. Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab 2009, 94:1236-1243.
32. Pi-Sunyer FX. The effects of pharmacologic agents for type 2 diabetes mellitus on body weight. Postgrad Med 2008, 120:5-17.
33. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002, 287:360-372.